CDIX Cardiff Lexington Corp
Services-Offices & Clinics of Doctors of Medicine · OTC · SEC CIK 811222 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.3%
TTM net income YoY-105.9%
TTM EPS YoY16.5%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin60.4%
Operating margin-10.9%
Net margin-92.1%
FCF margin—
EBITDA margin-10.8%
Returns
ROE-749.4%
ROA-32.9%
ROIC (approx.)-4.7%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets88.3%
Debt / equity12.95x
Current ratio0.91x
Interest coverage-0.14x
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.91M | $2.16M | $2.22M | $2.77M | $3.06M | $2.79M | $2.92M | $3.12M |
| Cost of revenue | $875,420 | $977,242 | $904,225 | $1.01M | $1.15M | $1.09M | $1.08M | $1.10M |
| Gross profit | $1.04M | $1.18M | $1.32M | $1.76M | $1.91M | $1.70M | $1.84M | $2.02M |
| SG&A expense | $1.20M | $1.36M | $1.16M | $1.84M | $1.22M | $987,319 | $1.28M | $1.44M |
| Operating income | -$536,666 | -$544,643 | -$511,159 | -$696,304 | $643,279 | $609,677 | $543,934 | $332,147 |
| Interest expense | $2.47M | $2.14M | $1.91M | $2.23M | $1.77M | $1.84M | $993,114 | $1.24M |
| Pretax income | — | — | — | -$2.92M | -$1.14M | -$1.23M | -$450,777 | -$910,342 |
| Net income | -$3.21M | -$2.48M | -$3.09M | -$2.69M | -$1.14M | -$1.23M | -$450,777 | -$910,342 |
| EBITDA | -$536,433 | -$544,390 | -$510,566 | -$695,542 | $644,041 | $610,440 | $547,299 | $335,512 |
| EPS (basic) | -0.22 | -0.18 | -0.23 | — | -0.21 | -0.24 | -0.14 | — |
| EPS (diluted) | -0.22 | -0.18 | -0.23 | — | -0.21 | -0.24 | -0.14 | — |
| Weighted avg. shares (diluted) | 15.72M | 15.27M | 14.52M | — | 6.58M | 6.19M | 5.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $584,319 | $217,654 | $683,507 | $318,535 | $232,033 | $559,715 | $996,758 | $1.19M |
| Receivables | $23.40M | $23.73M | $22.89M | $22.07M | $20.70M | $19.19M | $17.50M | $15.93M |
| Current assets | $24.22M | $24.30M | $23.86M | $22.59M | $21.04M | $19.87M | $18.61M | $17.21M |
| PP&E, net | $1,874 | $2,107 | $2,360 | $2,953 | $3,715 | $4,477 | $5,239 | $21,198 |
| Goodwill | $5.67M | $5.67M | $5.67M | $5.67M | $5.67M | $5.67M | $5.67M | $5.67M |
| Total assets | $30.58M | $30.68M | $30.29M | $29.09M | $27.61M | $26.51M | $25.33M | $23.93M |
| Current liabilities | $28.51M | $26.61M | $24.36M | $25.83M | $22.38M | $20.29M | $17.89M | $15.89M |
| Short-term debt | — | — | — | — | — | $0 | $0 | $3.62M |
| Long-term debt | $25.03M | $22.73M | — | $18.56M | $15.07M | $13.11M | $10.70M | $9.21M |
| Total debt | $25.03M | $22.73M | — | $18.56M | $15.07M | $13.11M | $10.70M | $12.83M |
| Total liabilities | $28.99M | $27.10M | $24.63M | $26.01M | $22.60M | $20.54M | $18.23M | $16.32M |
| Shareholders' equity | -$283,512 | $1.76M | $3.88M | -$2.47M | -$364,430 | $753,604 | $2.04M | $2.69M |
| Net debt | $24.44M | $22.51M | — | $18.24M | $14.84M | $12.55M | $9.71M | $11.64M |
| Shares outstanding | 17.03M | 15.28M | 15.17M | 13.70M | 19.90M | 19.68M | 15.33M | 5.10M |
| Cash flow statement | ||||||||
| Operating cash flow | $432,674 | -$651,919 | -$16,730 | -$389,974 | -$574,297 | -$260,275 | -$491,420 | -$722,559 |
| Financing cash flow | -$66,009 | $186,066 | $381,702 | $476,476 | $246,615 | -$176,768 | $299,993 | -$38,856 |
| Depreciation & amortization | $233 | $253 | $593 | $762 | $762 | $763 | $3,365 | $3,365 |
| Stock-based compensation | $369,981 | $366,939 | $664,196 | $615,787 | $41,188 | $97,500 | $0 | $244,500 |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $50,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.